Floatz logo

Cyclophosphamide

Triple-Negative Breast Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
65/ 100

Competitive context

427 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Capivasertib
AstraZeneca
Phase 3BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
mycosis fungoidesActive
BBB
Indicative · Phase 4
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →